Navigation Links
Sinus Dynamics Announced Treatment for MRSA with Nasal Nebulizer and Vancomycin
Date:10/24/2009

Vancomycin is used to treat bacterial infections by stopping or killing the bacteria responsible. When treatment using other antibiotics has failed, Vancomycin is the strongest option available. Now through Sinus Dynamic , Vancomycin is available in an aerosolized topical form which is effective against MRSA.

Westlake Village, CA (PRWEB) October 22, 2009 -- Sinus Dynamics™ announced today that the company has discovered treatment for Methicillin Resistant Staphylococcus Aureus (MRSA) with a nasally inhaled aerosolized form of Vancomycin, which can help patients and hospitals limit exposure to asymptomatic MRSA carriers.

Pharmacists at Sinus Dynamic can help the medical professionals address one of the largest fears of physicians, hospital administrators and patients alike (Hospital Acquired Infections). The Centers for Disease Control and Prevention estimates that hospital acquired infections are a direct result of 90,000 patient deaths each year in the U.S.A., while other organizations claim that the number is much higher.

Sinus Dynamics is the nation's leading compounding pharmacy specializing exclusively in the research and development of aerosolized formulas to treat bacterial and fungal sinus infections, sinus inflammation, and acute and chronic sinusitis. Sinus Dynamics treatments are self-administered by the patient using a small lightweight, electronic nebulizer. This medical device creates a 3.2 micron medicated mist, consisting of antibiotic, anti-fungal or anti-inflammatory medications. The medicated mist penetrates the sinus cavities to topically treat sinuses infected with MRSA or any other bacterial or fungal infection. With industry leading technology that enables physicians from across the country to prescribe our topical treatment method for their refractory sinus patients; Sinus Dynamics has the experience and resources in place to confront MRSA at its source; in the asymptomatic, sinus colonized MRSA carrier.

Sinus Dynamics is prepared to work with physicians and hospital administrators to implement this infection control therapy in an effort to help reduce MRSA infections across the country.

Contact Sinus Dynamics™ , a division of General Home Pharmacy, Inc. at 877-477-4276 or through their web site at www.sinusdynamics.com . Sinus Dynamics works with otolaryngologists, allergy & immunology specialists, infectious disease specialists, and pulmonary specialists throughout the United States; providing custom compounded medications, exclusively formulated to treat upper respiratory infections and inflammation through topical treatment. A network of representatives is available for on-site demonstrations.

###

Read the full story at http://www.prweb.com/releases/2009/10/prweb3011914.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Pharmacy Compounds Liquid Mupirocin for the Chronic Sinusitis Patient
2. SyntheMed Announces FDA Clearance of SinusShield(TM)
3. Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
4. Cellular Dynamics International Appoints Leroy Hood, M.D., Ph.D., and George Church, Ph.D., to its Scientific Advisory Board
5. Junying Yu, Leading Stem Cell Researcher, Joins Cellular Dynamics International
6. Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
7. Cellular Dynamics International Reprograms Blood Cells into Stem Cells
8. Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
9. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
10. The Global Active Pharmaceutical Ingredients (API) Market: A Frost & Sullivan Briefing on Changing Dynamics
11. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017  SeraCare Life Sciences, ... in vitro diagnostics manufacturers and clinical laboratories, ... first multiplexed Inherited Cancer reference material ... by next-generation sequencing (NGS). The Seraseq™ Inherited Cancer ... input from industry experts to validate the ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
(Date:3/23/2017)... 2017 According to a report by Transparency ... fragmented due to the presence of a large pool of participants; ... Fisher , and Sigma-Aldrich, compete with each other in this market. ... more than 76% of this market in 2016.  ... As of now, a large number ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... monitoring solutions, today announced the hire of Dr. Sigmund “Sig” Floyd as Vice ... applications, strategic partnerships and joint development activities. , “Dr. Floyd’s career has spanned ...
Breaking Biology Technology:
(Date:2/27/2017)... 27, 2017   Strategic Cyber Ventures , the ... led a $3.5 million investment in  Polarity , the ... Ventures is DC based and is led by cybersecurity ... . Ron Gula , also a longtime cybersecurity ... in this series A round of funding. This new ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/10/2017)... , Feb 10, 2017 Research ... report "Personalized Medicine - Scientific and Commercial Aspects" ... ... medicine. Diagnosis is integrated with therapy for selection of treatment ... early detection and prevention of disease in modern medicine. Biochip/microarray ...
Breaking Biology News(10 mins):